Last reviewed · How we verify

NCT03880448

Metronidazole vs Placebo as Adjuncts to Periodontal Surgery for Patients Positive to Porphyromonas Gingivalis

Completed NA Last updated 20 March 2019
What this trial tests

NA trial testing Metronidazole in Periodontitis in 17 participants. Completed in 15 January 2018.

Timeline
19 September 2012
Primary endpoint
15 January 2018
15 January 2018

Quick facts

Lead sponsorUniversidad Complutense de Madrid
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment17
Start date19 September 2012
Primary completion15 January 2018
Estimated completion15 January 2018
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universidad Complutense de Madrid — full company profile →

Who can join

Eligibility, any sex, with Periodontitis or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine whether the use of a systemic antimicrobial (metronidazole) as an adjunct to periodontal surgery provides additional clinical and microbiological beneficial effects compared to periodontal surgery alone plus a placebo, in patients with non treated periodontitis (stage III and IV) positive to Porphyromonas gingivalis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Metronidazole

Trials testing the same drug.

Other recruiting trials for Periodontitis

Currently open trials in the same condition.

Other Universidad Complutense de Madrid trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing